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Abstract 
Background 
There is evidence of statin benefit among patients with diabetes regardless of their cholesterol 
levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription 
of statins in clinical practice. This study aimed to assess statin prescriptions and associated 
factors among patients with type 2 diabetes in Botswana.  
Methods 
The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a 
specialised diabetes clinic at Gaborone Botswana. We assessed the proportion of statin-eligible 
patients who were prescribed statins and evaluated the adjusted associations between various 
factors and statin prescription. 
Results 
Overall, 477(95.4%) participants were eligible for a statin prescription. Clinicians prescribed 
statins in 217(45.5%%; 95% confidence interval[CI]: 41.1%-50.0%) of eligible participants, and 
only one(4.4%) ineligible participant. The probability of statin prescription was high in 
participants with high baseline low-density lipoprotein cholesterol(risk ratio [RR]:1.49; 95%CI: 
1.17 - 1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00 - 1.03) and the presence of 
chronic kidney disease (RR: 1.35; 95%CI: 1.06 - 1.74). 
Conclusion 
Most patients with type 2 diabetes were not receiving statins. Clinicians did not consider most 
guideline-recommended indications for statin prescription. The findings call for improvement in 
diabetes quality of care by implementing evidence-based guideline recommendations.  
Keywords: statin, type 2 diabetes mellitus, prescription and Botswana 
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Background 
Cardiovascular disease(CVD), which includes coronary artery disease (CAD), cerebrovascular 
accident, and peripheral arterial disease(PAD), are common and contribute to over two-thirds 
of mortality among patients with type 2 diabetes mellitus[1-3]. Although the presence of type 2 
diabetes alone confers the highest risk for CVD of any single risk factor, the coexistence of 
other cardiovascular risk factors is a common phenomenon[3, 4]. Consequently, guidelines 
advise screening and optimal treatment of CVD risk factors in people with diabetes[5, 6]. 
Besides, prescribing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors(statins) 
among patients with type 2 diabetes reduces the risk of major CVD events by 23%-33%[7-9]. 
There is evidence of statin benefit among patients with diabetes regardless of their low-density 
lipoprotein cholesterol(LDL-C) values or prior CVD history[7, 9-14].  For each mmol/l reduction 
in LDL-C, there is evidence of a 9 % relative reduction in all-cause mortality in patients with 
diabetes[15]. Irrespective of LDL-C, guidelines recommend statins for patients with diabetes 
aged ≥ 40 years without atherosclerotic cardiovascular disease(ASCVD), or those who are 
younger than 40 years but with existing ASCVD or additional risk factors[5, 6]. While some 
studies in developed countries have reported high use of statins among patients with type 2 
diabetes, there has generally been under-prescription of statins across many countries[16-18]. 
Statin prescription ranges between 0% and 100% in developed countries[17-20]. The 
proportion of patients with type 2 diabetes in Africa receiving a statin currently ranges between 
3 and 13%[21-23].  The suboptimal utilisation of statin therapy in Africa is due to many factors, 
but mainly limited access to standard diabetes care because of the high cost of tests and 
medications[22]. Affordability is a critical issue in several African countries where there is no 
universal healthcare, with the cost of medicines accounting for up to 70% of total healthcare 
expenditure, much of which is out-of-pocket[24, 25]. This is a concern given the high growth 
rates of cardiovascular diseases in sub-Saharan African countries and current poor control of 
cardiovascular diseases [26-30]. The underuse of statins significantly increases the incidence of 
cardiovascular events and associated mortality[31]. Although healthcare is free in Botswana, 
factors not related to cost may still affect the uptake of statins in patients with diabetes. This is 
an issue given current prevalence rates of diabetes in Botswana and the resultant impact on 
morbidity and mortality[32]. Currently, there is no study assessing statin prescriptions among 
patients with type 2 diabetes in Botswana. We aimed to address this by evaluating the extent 
of statin prescriptions among patients with diabetes in Botswana. Our secondary aim was to 
determine factors associated with statin prescriptions among Type 2 diabetes. Subsequently, 
we will use the findings to develop appropriate strategies to address the situation identified 
concerns. 
Methods 
Study design  
We conducted a secondary analysis of data from a previous study among type 2 diabetics at a 
specialised diabetes clinic in Gaborone, Botswana. Any concerns with the management of 
diabetic patients in this dedicated leading clinic are likely to be exacerbated in non-specialist 
centres such as primary healthcare centres.  
Participant recruitment and data collection 
The original study took place between August 2017 and February 2018[33]. The primary 
objective of the original study was to assess glycemic, low-density lipoprotein, and 
hypertension control in patients with type 2 diabetes. The study included 500 randomly 
selected patients with type 2 diabetes aged ≥ 18 years who had received care from the clinic for 
at least three months before data collection.  Demographic data(age, sex, occupation, 
educational attainments, and marital status), duration of diabetes,  and the type of diabetes 
medications were collected. Other information was the history of hypertension, lipid disorders, 
ischemic heart diseases, stroke or peripheral vascular disease. We also recorded data on the 
use of medications for hypertension and lipid disorders (including statins), and anthropometric 
measurements (weight, height, hip and waist circumferences).  
For the present study, we evaluated the extent of statin prescriptions among the participants in 
the dataset. The primary outcome measure was receiving a statin prescription among statin-
eligible participants. We assessed statin eligibility based on the Society for Endocrinology, 
Metabolism, and Diabetes of South Africa(SEMDSA) guidelines[6].  According to SEMDSA, the 
eligibility for statin prescribing included any cardiovascular disease(CVD) or chronic kidney 
disease(CKD), participant’s age above 40 years, and diabetes duration longer than ten years. 
Also, the presence of one or more additional cardiovascular risk factors, i.e. hypertension, 
cigarette smoker,  low high-density lipoprotein cholesterol(HDL-C) level, family history of early 
CAD, and any albuminuria were the other eligibility criteria[6]. Thus, we assessed the 
association of the above eligibility criteria for statin prescribing. Other independent variables 
included baseline serum LDL-C, body mass index(BMI), waist-hip ratio(WHR) and education 
attainment.  
Definition of terms 
The diagnosis of hypertension was based on the self-reported history of hypertension, the use 
of hypertension-lowering medications or sustained blood pressure ≥140/90 mmHg in more 
than one visit[34]. We defined CVD as the history of CAD, cerebrovascular diseases(ischemic 
stroke, transient ischemic attacks), or peripheral vascular diseases(PAD)[6]. CAD was any 
documented definite or probable myocardial infarction, CAD-related revascularisation(surgery, 
angioplasty, stenting, or any combination of these), or stable angina in patients’ medical 
records[35]. Cerebrovascular and peripheral vascular diseases were extracted from patients’ 
medical records as defined by the treating physician. Smoking status was a documented self-
report of current smoking habits. We estimated glomerular filtration rate(eGFR) using the 
Modification of Diet in Renal Disease(MDRD), and classified patients with eGFR < 60 
ml/minute/1.73m2 as having chronic kidney disease and an increased risk of a cardiovascular 
event[5, 6, 36]. Body mass index(BMI) was categorized into underweight for BMI <18.5 kg/m2; 
normal for BMI of 25.0–29.9 kg/m2; or obese for BMI ≥30 kg/m2[37]. We measured waist and 
hip circumferences using standard procedures and defined WHR ≥ 0.85 for women and ≥ 0.90 
for men as high[38]. Dipstick proteinuria appeared as negative (−), trace, (+), (++), or (+++) in 
the dataset. We classified proteinuria in individuals with  ≥(+) dipstick proteinuria results. For 
patients already on lipid-lowering medications and whose baseline 'untreated' levels of lipid 
profile were not available, we estimated the LDL-C levels before the initiation of statin 
treatment as in previous studies[39]. The adjustment was made based on the assumption that 
most patients received atorvastatin (the only statin available in the public sector in Botswana) 
at a dosage of at least 10mg per day. With an estimated adherence of 58.2 %, we calculated the 
baseline LDL-C levels by assuming that the measured LDL-C is a result of a 25% reduction from 
baseline[39]. Baseline LDL-C levels above 4.13 mmol/l were considered high[40]. 
Statistical analysis 
Clean data were imported and analysed using Stata Version 14(Stata Corp, College Station, TX). 
Categorical variables are presented as percentages and continuous variables as a 
mean(standard deviation[SD]) or median [first–third quartiles]. Comparison of clinical and 
demographic factors by gender and statin use was made using Chi-square or Fisher’s exact tests 
for categorical variables, and independent student’s t-tests or Wilcoxon rank-sum test for 
continuous variables as appropriate. A 2-sided p-value < 0.05 was considered as statistically 
significant. To assess for independent predictors for statin prescribing, generalised linear 
models for the binomial family were used, and a log link was specified to obtain relative risks 
and 95% confidence intervals. All factors with p < 0.2 on univariate analysis were added to the 
multivariable model. We used a backward selection modelling method, with probabilities set at 
0.05 and 0.1 for inclusion and exclusion; respectively. We report adjusted risk ratios (RRs), 95% 
CIs, and p-values. We required a sample size of 477 to produce a two-sided 95% confidence 
interval with a width equal to 3.01% based on the assumptions of approximately 13% statin use 
among patients with type 2 diabetes in Botswana[22].  
  
Results 
Of the 500 patients in the dataset, the mean(SD) age was 58.9(12.2) years, 330 (66%) were 
females. Table 1 summarises the patients' characteristics by gender. The majority(96.7%) of 
participants aged ≥ 40 years and women were significantly older than men. Approximately a 
third (34.4%) of participants had a diabetes duration of over ten years. Hypertension(84.7%) 
and obesity(51.6%) were prevalent, especially in female participants. Overall, CKD(11.3%), 
proteinuria(10.7%), CVD (8.8%), and smoking(3.4%) were uncommon.  The mean(SD) baseline 
LDL-C was 3.1(1.2) mmol/L, significantly higher in female than male participants. 
[Table 1: Demographic and clinical characteristics of patients with type 2 diabetes at a 
specialised Diabetes clinic in Gaborone (N= 477)]  
 
Statin eligibility and prescribing rates 
Of the 500 participants, 477(95.4%) were eligible for a statin prescription. Clinicians prescribed 
statins (exclusively atorvastatin) in 217(45.5%; 95%CI:41.1%-50.0%) of statin-eligible 
participants, and only one(4.4%;95%CI:5.1%-28.4%) ineligible participants. Seven(1.5%) of all 
participants received prescriptions of other lipid-lowering medications alone or in combinations 
with statins.  Of those who were eligible for statins, statin-prescribed individuals differed from 
those without prescriptions in several parameters on univariate analysis(Table 2). Relative to 
the statin-non-prescribed group, the statin-prescribed group had a longer duration of 
diabetes(8.9 years vs. 6.0 years; p < 0.001); were older (61.5 years  vs 59.2 years ; p = 0.018), 
and had a a higher proportion of hypertensive patients(85.5% vs 81.5%; p<0.036),   a higher 
proportion of those on antihypertensive(85.7% vs 78.1%, p<0.032), a higher proportion of 
participants with CKD(17.2% vs 6.6%;  p= 0.006), and a higher baseline LDL-C(3.3 vs 2.9 mmol/L; 
p <0.003). The two groups did not differ significantly in the presence of CVD, proteinuria and 
gender. 
[Table 2: Factors associated with statin prescription among statin-eligible patients with type 2 
diabetes at a specialised Diabetes clinic in Gaborone (N= 477)]. 
Multivariable analysis 
In the multivariable model which examined adjusted associations between statin prescription 
and various factors, the best fit had the following covariates: age, the duration of diabetes, BMI, 
hypertension a high baseline LDL-C, CKD, CVD, and proteinuria.   Increasing diabetes duration 
was associated with an increased likelihood (RR: 1.01; 95%CI 1.00 - 1.03) of receiving a statin 
prescription (Table 3), as was the presence of CKD(RR: 1.35; 95%CI: 1.06 – 1.74) and a high 
baseline LDL-C(RR: 1.49; 95%CI: 1.17 - 1.89). Patients’ age, BMI, history of CVD, and a diagnosis 
of hypertension were not associated with statin prescribing after adjustment for the other 
variables in the model. 
[Table 3 Adjusted relative risks for associations between various factors and statin 
prescription among statin eligible patients with diabetes at a specialised diabetes clinic in 
Botswana]  
  
Discussion  
Among patients with type 2 diabetes at a specialised diabetes clinic in Botswana, less than half 
of the statin-eligible patients received a statin prescription. The longer duration of diabetes, a 
higher baseline LDL-C and the presence of chronic kidney disease were independently 
associated with the tendency to prescribe statins. 
The under-prescription of statins in our cohort is a concern since the use of statins appreciably 
reduces cardiovascular events and mortality in patients with diabetes irrespective of their LDL-C 
levels[7, 9-13]. Although the proportion of patients with diabetes who are prescribed statins 
varies substantially worldwide, there is a low prescribing of statins both in developing and 
developed countries[18, 19, 21-23, 41-44]. The percentage of patients with diabetes who 
received statins(45.5%) in our cohort is consistent with findings from developed countries 
where 25% to 73% of patients with diabetes are prescribed statins despite recommendations 
from the guidelines[18, 19, 41-43]. The proportion of participants with a statin prescription in 
our cohort was higher than those reported in some cohorts in developed countries, such as 
Germany (25%) and Great Britain (33%)[18, 41]. While the finding of a comparatively higher 
statin prescription in our setting than some other settings in developed countries is 
encouraging, there is no reason for complacency as more than half of our patients were 
without CVD protection by statins. Similar to developed countries, one potential explanation for 
low statin prescribing rates among our patients with diabetes is poor adherence to 
guidelines[22, 44-46]. While there may be a fear of the association of statin therapy with a 
slightly increased risk of developing diabetes, the benefits of statins in reducing cardiovascular 
morbidity and mortality among patients with established diabetes should dispel these 
concerns[7-9, 47]. Several epidemiological studies have observed a lower proportion of statin 
prescription in patients with diabetes in Africa (3% to 13%) than in our cohort[21-23]. In 
addition to poor adherence to guidelines, the main reasons for low statin prescribing in Africa 
include limited access to these medicines due to their high cost, lack of facilities for monitoring 
lipid profiles while patients are on treatment, and unavailability of guidelines[22]. The 
availability of free consultations, tests and medications in Botswana might explain our higher 
statin prescribing rates than those in other African settings without universal health access.  
Irrespective of the reasons, it is imperative that statins are routinely prescribed to reduce the 
risk of CVD events in patients with type 2 diabetes[7-13, 15, 48].  
Our results of increasing statin prescribing with increasing diabetes duration also agree with 
previous research findings[49]. This is reassuring as a longer duration of diabetes leads to an 
increased risk of CVD. For this reason, guidelines recommend statins for patients with diabetes 
for more than ten years[5, 6]. Although this finding may suggest that clinicians correctly 
recognise a longer duration of diabetes as an indication for statin therapy, the results tend to 
agree with the fact that transmission of information between clinicians and patients about new 
medications requires time[50]. 
Another finding in our study was that the presence of chronic kidney disease increased the 
likelihood of statin prescribing. This finding is also encouraging as statins reduce mortality by up 
to 36% in patients with kidney failure[5, 6, 51, 52]. Besides, this finding is consistent with 
SEMDSA guideline recommendations of a statin for every patient with diabetes and CKD[6]. 
While the presence of any albuminuria is another marker of renal kidney disease used as an 
indication of statin use in people with diabetes, dipstick proteinuria was not associated with 
statin prescribing in our cohort. We can postulate that clinicians do not recognise proteinuria as 
a predictor of CVD and an indication for statins in patients with diabetes. We will investigate 
this further as it contrasts with Berthold et al. who reported increased odds of statin prescribing 
in type 2 diabetes patients with proteinuria in Germany[18] 
Our findings that a high baseline LDL-C increased the likelihood of statin prescribing agreed with 
those of Berthold at al. that showed an 11% increase in statin prescribing rates for every 0.26 
mmol/L increase in LDL-C[18]. Besides, this finding confirms the observation from previous 
studies that prescribers tend to respond more to the pre-treatment LDL-C value than to the 
patients’ overall CVD risk profile as described in clinical guidelines [9, 45]. Although there is a 
lack of local guidelines, the clinic adopted the SEMDSA guidelines which recommend statins 
along with lifestyle changes regardless of cholesterol levels for all patients with diabetes aged > 
40 with or without CVD[6]. Our findings that there is approximately a 50% increased likelihood 
of statin prescription in our cohort may suggest a need for deliberate efforts for improving the 
understanding and implementation of the adopted guidelines, and we will be taking this 
further. 
In most clinical guidelines, the presence of CVD, CKD, patients age, diabetes and presence of 
CVD risk factors such as hypertension, albuminuria and cigarette smoking are indicators of 
prescribing statins among patients with type 2 diabetes[5, 6]. The recommendations are based 
mainly on the rationale that the presence of any of the above factors is associated with an 
increased risk of CVD. Except for CKD and duration of diabetes, none of the other indications 
was a predictor of statin prescriptions in our cohort. Given the high prevalence of hypertension 
and other indications in our cohort, most participants would have qualified for statins if 
guideline recommendations were adhered to. As our clinic has adopted the SEMDSA guidelines, 
this finding is a concern and a call for efforts to improve its implementation for the benefit of 
this high-risk population. We will be following this up. 
We are mindful of the limitations of our study. We estimated the baseline LDL-C levels by a 25% 
adjustment of measured LDL. There was a risk of either overestimation or underestimation of 
the baseline LDL-C in case of significant errors in our assumptions of the dosage and the 
adherence of atorvastatin. Although measured LDL-C results were available for all the included 
participants, HDL cholesterol results were mostly missing. Guidelines consider HDL as one of 
the factors for statin prescriptions in patients with diabetes. However, all other indications for 
statin prescriptions were available in our cohort. We did not document the dosage of statin 
used in our cohort; hence, we are unable to determine whether moderate to high-intensity 
statins were prescribed as recommended by the guidelines. The study was also performed in 
one leading clinic, hence limiting the generalizability of the study findings to other facilities in 
the country. However, being one of the few specialised diabetes clinics in the country, our 
results likely represent the ‘best’ quality of diabetes care in Botswana. Consequently, 
highlighted concerns are likely to be higher in non-specialist healthcare facilities treating 
patients with type 2 diabetes in Botswana. 
Conclusion  
In conclusion, we believe this study provides a useful and reliable picture of current statin 
prescribing behaviour in Botswana despite the limitations mentioned above. There is under-
prescribing of statins in this high-risk population. The presence of CKD, high baseline LDL, and 
an increased duration of diabetes strongly influence statin prescriptions in patients with 
diabetes. Clinicians did not consider most guideline-recommended indications for statin 
prescription. By identifying gaps in the prescription of statins to patients with diabetes, the 
study provides a substantial opportunity for improvement in diabetes quality of care. 
Furthermore, the study findings suggest a need for further studies to investigate the reasons for 
statin under-prescription in our setting. We are following this up to provide future guidance for 
clinicians in Botswana treating patients with type 2 diabetes, with the results likely to be of 
interest to other sub-Saharan African countries with high rates of type 2 diabetes. 
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Tables  
 Table 1: Demographic and clinical characteristics of patients with type 2 diabetes at a 
specialised Diabetes clinic in Gaborone (N= 477)  
Characteristics 
All (N=477) Males (n= 160) Females (n= 317) 
Age, mean(SD), years 60.3(10.8) 56.8(11.5) 62.0(10.1) 
Age > 40 years n(%) 461(96.7) 150(93.8) 311(98.1) 
Diabetes duration, median, IQR, years 7(3-13) 8.9(3-14) 7 (3-13) 
Diabetes duration > 10 years 164 (34.4) 63(39.4) 101(31.9) 
BMI, mean (SD) kg/m2 30.7(6.0) 29.0(5.2) 31.6(6.1) 
 Normal weight n(%) 85(17.8) 39(24.4) 46(14.5) 
 Overweight n(%) 146(30.6) 59(36.7) 87(27.4) 
 Obese n(%) 246(51.6) 62(38.8) 184(58.0) 
Marital status    
 Living alone n(%) 247(51.8) 47(29.4) 200(63.1) 
 Living with a partner n(%) 230(48.2) 113(70.6) 117(36.9) 
Education status    
 ≤ Primary education, n(%) 306(64.1) 82(51.3) 224(70.7) 
 ≥ Secondary or tertiary, n(%) 171(35.9) 78(48.7) 93(29.3) 
WHR, mean (SD) 0.94(0.10) 0.97(0.08) 0.93(0.09) 
 Low WHR n (%) 79(16.6) 67(41.9) 12(3.8) 
 High WHR n (%) 398(83.4) 93(58.1) 305(96.2) 
Hypertension n (%) 404(84.7) 120(75.0) 284(89.6) 
Use of antihypertensive n (%) 389(81.6) 110(68.8) 279(88.0) 
Smoking n (%) 16(3.4) 12(7.5) 4(1.3) 
Lipid-lowering medications n (%) 224(47.0) 70(43.8) 154(48.6) 
 Statins n (%) 217(45.5) 68(42.5) 149(47.0) 
 Others n (%) 7(1.5) 2(1.6) 5(1.6) 
CVD n (%) 42(8.8) 15(9.4) 27(8.5) 
 PAD n (%) 11(2.3) 3(1.9) 8(2.5) 
 Coronary artery disease n (%) 12(2.5) 5(3.3) 7(2.2) 
 Cerebrovascular disease n (%) 22(4.6) 8(5.0) 14(4.4) 
CKD n (%) 54(11.3) 24(15.0) 30(9.5) 
Proteinuria n (%) 51(10.7) 27(16.9) 24(7.6) 
HbA1c mean (SD), % 8.4(2.4) 8.5(2.6) 8.3(2.3) 
Baseline LDL-C, mean (SD), mmol/L 3.1(1.2) 2.8(1.1) 3.3(1.2) 
 Normal 315(66.0) 113(70.6) 202(63.7) 
 High 59(12.4) 9(5.6) 50(15.8) 
 Missing  103(21.6) 38(23.8) 65(20.5) 
Legend: BMI- Body Mass Index, CKD – chronic kidney disease, CVD – cardiovascular disease, HbA1c – Haemoglobin A1c, IQR – 
interquartile range; LDL-C – low-density lipoprotein cholesterol, PAD – peripheral artery disease, SD – standard deviation; 
WHR – waist-hip ratio. 
 
 
Table 2: Factors associated with statin prescription among statin-eligible patients with type 2 
diabetes at a specialised Diabetes clinic in Gaborone (N= 477) 
Characteristics 
Statin not prescribed (n= 
260) 
Statin prescribed 
(n= 217) 
P-value 
Sex    
 Males, n (%) 92(35.4) 68(31.3) 
0.351 
 Female, n (%) 168(64.6) 149(68.7) 
Diabetes duration, median, IQR, 
years 
6(2 – 12) 8.9(4 – 15) <0.001 
 Duration ≤ 10 years 179(68.9) 134(61.8) 
0.104 
 Diabetes duration > 10 years 81(31.1) 83(38.2) 
Age, mean (SD), years 59.2(10.8) 61.5(10.7) 0.018 
 Age ≤ 40 years, n (%) 12(4.6) 4(1.8) 
<0.094 
 Age > 40 years n (%) 248(95.4) 213(98.2) 
Marital status    
 Living alone n (%) 135(51.9) 112(51.6) 
0.946 
 Living with a partner n (%) 125(48.1) 105 (48.4) 
Education status    
 ≤ Primary education, n (%) 166(63.9) 140(64.2) 
0.879 
 ≥ Secondary or tertiary, n (%) 94(36.1) 77(35.8) 
Hypertension n (%) 212(81.5) 192 (88.5) 0.036 
Antihypertensive use n (%) 203(78.1) 186(85.7) 0.032 
Smoking 13(5.0) 3(1.4) 0.029 
CVD, n (%) 20(7.7) 22(10.1) 0.538 
 PAD, n (%) 7(2.7) 4(1.8) 0.625 
 Coronary artery disease n (%) 6(2.3) 6(2.8) 0.751 
 Cerebrovascular diseases n (%) 9(3.5) 13(6.0) 0.190 
BMI, mean (SD) kg/m2 30.3(5.7) 31.2(6.2) 0.113 
 Normal weight n (%) 50(19.2) 35(16.1) 
0.669  Overweight n (%) 79(30.4) 67(30.9) 
 Obese n (%) 135(47.9) 115(52.8) 
WHR, mean (SD) kg/m2 0.94(0.08) 0.95(0.10) 0.106 
 Low WHR n (%) 46(17.7) 33(15.2) 
0.467 
 High WHR n (%) 214(82.3) 184(84.8) 
CKD, n (%) 20(7.7) 34 (15.7) 0.006 
Proteinuria, n (%) 30 (11.5) 21(9.7) 0.512 
HbA1c mean (SD), % 8.4(2.6) 8.4(2.2) 0.948 
Baseline LDL-C mean (SD), mmol/L 2.9(0.9) 3.3(1.4) 0.003 
 Normal 177(68.1) 120(55.3) 
<0.001 
 High  17(6.5) 42(19.4) 
 Missing 66(25.4) 55(25.3)  
Legend: BMI- Body Mass Index, CKD – chronic kidney disease, CVD – cardiovascular disease, HbA1c – 
Haemoglobin A1c, IQR – interquartile range; LDL-C – low-density lipoprotein cholesterol, PAD – 
peripheral artery disease, SD – standard deviation; WHR – waist-hip ratio. 
  
Table 3 Adjusted relative risks for associations between various factors and statin prescription 
among statin eligible patients with diabetes at a specialised diabetes clinic in Botswana  
Characteristic Risk ratio 95% Conf. Interval p-value 
Age 1.006 0.994-1.017 0.362 
CKD 1.354 1.055-1.738 0.017 
Hypertension 1.336 0.846-2.110 0.213 
BMI 1.014 0.994-1.034 0.16 
High baseline LDL 1.488 1.173-1.887 0.001 
Diabetes duration, years 1.014 1.000-1.027 0.048 
Proteinuria 0.979 0.644-1.488 0.922 
CVD 0.901 0.623-1.303 0.581 
Legend: BMI- Body Mass Index, CKD – chronic kidney disease, CVD – cardiovascular disease, LDL-C – 
low-density lipoprotein cholesterol. 
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